UNSPSC 51314323: Brompheniramine/guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314323 Brompheniramine/guaifenesin/pseudoephedrine is a Commodity code, but the recent state and local procurement activity tagged under it does not reflect purchases of this specific pharmaceutical combination. Instead, the opportunities show state and local buyers sourcing naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The code appears to see limited relevant recent activity; the three most recent opportunities address opioid-reversal agents and broader pharmaceutical distribution channels rather than the antihistamine-decongestant-expectorant combination the code nominally describes. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance spanning multiple states including Oregon).

The geographic spread of tagged opportunities includes Florida, Texas, Minnesota, and Oregon. Representative recent solicitations include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems, an IFB posted June 30, 2026, with a response deadline of July 26, 2023 (note: date inconsistency in source); the Texas HHS Commission's RFI No. HHS0017013 for direct-to-manufacturer prescription capabilities, issued April 3, 2026; and MMCAP's S1070000015802 for generic multi-source pharmaceuticals and OTC products, an RFP posted January 20, 2026, with proposals due March 26, 2026. The MMCAP opportunity is administered through the Minnesota Department of Administration's Office of State Procurement and spans multiple participating jurisdictions. None of these recent opportunities directly matches the brompheniramine/guaifenesin/pseudoephedrine product code nominal scope, indicating either a classification mismatch in the source data or minimal current procurement demand for this specific combination under its assigned code.